BiomX Wins NYSE American Approval for Compliance Plan Through September 2027
PHGE•NYSE American has accepted BiomX's plan to regain compliance, granting a period through September 25, 2027. The plan addresses a $1.302 million stockholders’ deficit reported as of December 31, 2025, and company stock will remain listed pending periodic reviews of its progress.
1. Compliance Plan Acceptance
NYSE American has accepted the plan BiomX submitted on April 24, 2026 to address its listing deficiencies, granting the company until September 25, 2027 to meet capital requirements and maintain continuous listing on the NYSE American.
2. Initial Non-Compliance Details
The company’s written notice of non-compliance stemmed from a $1.302 million stockholders’ deficit as of December 31, 2025 and five consecutive years of net losses and losses from continuing operations under Sections 1003(a)(i)-(iii) of the listing guide.
3. Monitoring and Next Steps
During the compliance period, BiomX will undergo periodic reviews by NYSE Regulation and undertake the initiatives outlined in its plan to restore required equity levels, with its common stock remaining tradable under existing continued listing standards.
